Robinson Cole LLP
High Contrast Mode
Marquee

Clinical Laboratories + Pathology Laboratories

Strategic Counsel for a Rapidly Evolving Regulatory Landscape 

At Robinson+Cole, we provide comprehensive legal support to clinical and pathology laboratories traversing the complex and ever-evolving regulatory environment. Our cross-disciplinary team advises on transactional structuring, regulatory compliance, and litigation defense — helping our clients remain compliant, competitive, and protected. Our team services laboratories to address their business needs in a compliant manner to navigate operational and legal challenges. 

We regularly publish in laboratory journals, speak at industry events, and lead webinars — ensuring our team stays at the forefront of regulatory and legal trends.  

Our Services for Clinical Laboratories 

Our firm provides strategic counsel to clinical and pathology laboratories. With our industry insight and regulatory fluency, we help clients structure deals that align with both their business goals and compliance obligations. Such services include, but are not limited to: 

Transactional 

  • Structuring joint ventures, acquisitions, and affiliations; 
  • Drafting and negotiating laboratory service agreements and marketing agreements; and
  • Conducting regulatory and compliance due diligence. 

Regulatory Compliance 

  • Advising on reimbursement issues, lab-to-lab billing requirements, and overall billing compliance; 
  • Reviewing and drafting sales and marketing practices and advising on compliance;
  • Counseling on the Anti-Kickback Statute, the Stark Law, the Eliminating Kickbacks in Recovery Act, and other fraud and abuse laws; 
  • Developing compliance plans and training; 
  • Providing guidance on CLIA certification and state licensure; 
  • Advising on HIPAA (Health Insurance Portability and Accountability Act) and data privacy compliance; 
  • Assisting with internal compliance audits and policy development; and  
  • Providing representation before CMS and in state agency matters. 

Litigation and Enforcement Defense 

  • Defending against government investigations and enforcement actions; 
  • Responding to audits, subpoenas, and qui tam complaints; 
  • Negotiating corporate integrity agreements and other settlements with the U.S. Department of Health and Human Services Office of Inspector General; and
  • Managing appeals of adverse regulatory determinations. 

Why Clients Choose Us 

  • Long-standing industry knowledge: Our attorneys understand the operational realities of clinical and pathology  labs. 
  • Proactive risk management: We help clients anticipate and mitigate compliance risks before they escalate. 
  • Integrated legal solutions: From deal structuring to defense strategy, we offer end-to-end support. 

People


Experience


Represented MD Labs in First Circuit Victory for Clinical Lab in False Claims Act Appeal

Successfully represented MD Labs and its owners in defending against False Claims Act allegations in U.S. ex rel. Omni Healthcare Inc. v. MD Spine Solutions LLC et al., securing summary judgment in the District of Massachusetts and a unanimous affirmation by the U.S. Court of Appeals for the First Circuit. This landmark decision clarified that clinical laboratories may rely on doctor’s orders to show that the test is “reasonable and necessary” and confirmed that commissions to independent contractors are not per se illegal — setting an important precedent for clinical laboratories nationwide.

Read More
Represented MD Labs in First Circuit Victory for Clinical Lab in False Claims Act Appeal

Publications


New Year Brings Old Obligations with a Recent Twist: PAMA Reporting is Back teaser
February 3, 2026

New Year Brings Old Obligations with a Recent Twist: PAMA Reporting is Back

The ColLABorative Brief
DOJ Enforcement of Clinical Laboratories: Trends from Q4 2025 teaser
February 2, 2026

DOJ Enforcement of Clinical Laboratories: Trends from Q4 2025

The ColLABorative Brief
Eliminating Kickbacks in Recovery Act – 2025 Updates and Looking to 2026 teaser
February 2, 2026

Eliminating Kickbacks in Recovery Act – 2025 Updates and Looking to 2026

The ColLABorative Brief
New Year Brings Old Obligations with a Recent Twist: PAMA Reporting is Back teaser
February 3, 2026

New Year Brings Old Obligations with a Recent Twist: PAMA Reporting is Back

The ColLABorative Brief
DOJ Enforcement of Clinical Laboratories: Trends from Q4 2025 teaser
February 2, 2026

DOJ Enforcement of Clinical Laboratories: Trends from Q4 2025

The ColLABorative Brief
Eliminating Kickbacks in Recovery Act – 2025 Updates and Looking to 2026 teaser
February 2, 2026

Eliminating Kickbacks in Recovery Act – 2025 Updates and Looking to 2026

The ColLABorative Brief
Search Bars, Chatbots, and Tracking Pixels: Practical Steps Labs Can Take to Reduce CIPA Risk in 2026 teaser
February 2, 2026

Search Bars, Chatbots, and Tracking Pixels: Practical Steps Labs Can Take to Reduce CIPA Risk in 2026

The ColLABorative Brief
Medicare Part B Lab Spending Increased in 2024: Here’s what the Latest OIG Report Reveals teaser
February 2, 2026

Medicare Part B Lab Spending Increased in 2024: Here’s what the Latest OIG Report Reveals

The ColLABorative Brief
South Carolina Lab Settles False Claim Act Case – A Study on Commercial Reasonableness and Disguised Kickbacks teaser
January 12, 2026

South Carolina Lab Settles False Claim Act Case – A Study on Commercial Reasonableness and Disguised Kickbacks

Health Law Diagnosis
OIG Greenlights Sponsored Diagnostic Testing in Advisory Opinion 25-07 teaser
November 17, 2025

OIG Greenlights Sponsored Diagnostic Testing in Advisory Opinion 25-07

The ColLABorative Brief
Clean Slate: San Antonio Lab Executives Exonerated in Health Care Fraud Case teaser
November 17, 2025

Clean Slate: San Antonio Lab Executives Exonerated in Health Care Fraud Case

The ColLABorative Brief
From Risk to Readiness: Navigating the Payor Audit Landscape teaser
November 17, 2025

From Risk to Readiness: Navigating the Payor Audit Landscape

The ColLABorative Brief


Search Bars, Chatbots, and Tracking Pixels: Practical Steps Labs Can Take to Reduce CIPA Risk in 2026 teaser
February 2, 2026

Search Bars, Chatbots, and Tracking Pixels: Practical Steps Labs Can Take to Reduce CIPA Risk in 2026

The ColLABorative Brief
Medicare Part B Lab Spending Increased in 2024: Here’s what the Latest OIG Report Reveals teaser
February 2, 2026

Medicare Part B Lab Spending Increased in 2024: Here’s what the Latest OIG Report Reveals

The ColLABorative Brief
South Carolina Lab Settles False Claim Act Case – A Study on Commercial Reasonableness and Disguised Kickbacks teaser
January 12, 2026

South Carolina Lab Settles False Claim Act Case – A Study on Commercial Reasonableness and Disguised Kickbacks

Health Law Diagnosis
OIG Greenlights Sponsored Diagnostic Testing in Advisory Opinion 25-07 teaser
November 17, 2025

OIG Greenlights Sponsored Diagnostic Testing in Advisory Opinion 25-07

The ColLABorative Brief
Clean Slate: San Antonio Lab Executives Exonerated in Health Care Fraud Case teaser
November 17, 2025

Clean Slate: San Antonio Lab Executives Exonerated in Health Care Fraud Case

The ColLABorative Brief
From Risk to Readiness: Navigating the Payor Audit Landscape teaser
November 17, 2025

From Risk to Readiness: Navigating the Payor Audit Landscape

The ColLABorative Brief

Events


Upcoming

Redefining Audit Preparedness & Compliance for Future-Proof Payments

May 14 2026
Q1 Productions’ 33rd Tri-Annual Diagnostic Coverage & Reimbursement Conference
Past

Under OIG Scrutiny: Translating 2025 Enforcement Trends Into Actionable Strategies for Laboratory Compliance, Test Utilization Optimization, and Enterprise-Wide Risk Mitigation in 2026

Apr 28 2026
2026 Executive War College
Upcoming

Redefining Audit Preparedness & Compliance for Future-Proof Payments

May 14 2026
Q1 Productions’ 33rd Tri-Annual Diagnostic Coverage & Reimbursement Conference
Past

Under OIG Scrutiny: Translating 2025 Enforcement Trends Into Actionable Strategies for Laboratory Compliance, Test Utilization Optimization, and Enterprise-Wide Risk Mitigation in 2026

Apr 28 2026
2026 Executive War College
Past

The Slippery Slope to Enforcement: How Payor Audits Trigger Government Action—and How to Identify Compliance Risk Early

Apr 28 2026
2026 Executive War College
Past

Lab Compliance and Test Utilization: Prepare for 2026 and Beyond

Mar 25 2026
Whitehat Communications’ Point of Care Group Webinar Series
Past

Redefining Audit Preparedness & Compliance for Future-Proof Payments

Mar 18 2026
Q1 Productions’ 32nd Tri-Annual Diagnostic Coverage & Reimbursement Conference
Past

Redefining Audit Preparedness & Compliance for Future-Proof Payments

Dec 9 2025
Q1 Productions’ Tri-Annual Diagnostic Coverage & Reimbursement Conference
Past

The Slippery Slope to Enforcement: How Payor Audits Trigger Government Action—and How to Identify Compliance Risk Early

Apr 28 2026
2026 Executive War College
Past

Lab Compliance and Test Utilization: Prepare for 2026 and Beyond

Mar 25 2026
Whitehat Communications’ Point of Care Group Webinar Series
Past

Redefining Audit Preparedness & Compliance for Future-Proof Payments

Mar 18 2026
Q1 Productions’ 32nd Tri-Annual Diagnostic Coverage & Reimbursement Conference
Past

Redefining Audit Preparedness & Compliance for Future-Proof Payments

Dec 9 2025
Q1 Productions’ Tri-Annual Diagnostic Coverage & Reimbursement Conference